Citigroup says it sees an unmet need for Esperion's oral LDL cholesterol lowering agent ETC-1002. It assumed coverage of the stock with a Buy rating and raised its price target for shares to $130 from $67.
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Altamira Therapeutics... To see the rest of the story go to thefly.com. See Story Here
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Altamira Therapeutics... To see the rest of the story go to thefly.com. See Story Here